Columbus Hill Capital Management L.P. lessened its stake in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 2.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 968,221 shares of the specialty pharmaceutical company’s stock after selling 26,907 shares during the quarter. Valeant Pharmaceuticals International comprises approximately 1.7% of Columbus Hill Capital Management L.P.’s holdings, making the stock its 23rd biggest holding. Columbus Hill Capital Management L.P. owned approximately 0.28% of Valeant Pharmaceuticals International worth $16,750,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. ValueAct Holdings L.P. boosted its holdings in shares of Valeant Pharmaceuticals International by 20.0% in the 1st quarter. ValueAct Holdings L.P. now owns 17,997,224 shares of the specialty pharmaceutical company’s stock valued at $198,509,000 after purchasing an additional 3,002,963 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Valeant Pharmaceuticals International by 4.2% in the 2nd quarter. Vanguard Group Inc. now owns 7,274,717 shares of the specialty pharmaceutical company’s stock valued at $125,853,000 after purchasing an additional 294,643 shares during the last quarter. Bank of Montreal Can boosted its holdings in shares of Valeant Pharmaceuticals International by 9.8% in the 2nd quarter. Bank of Montreal Can now owns 6,330,670 shares of the specialty pharmaceutical company’s stock valued at $109,521,000 after purchasing an additional 564,215 shares during the last quarter. OppenheimerFunds Inc. boosted its holdings in shares of Valeant Pharmaceuticals International by 17.1% in the 1st quarter. OppenheimerFunds Inc. now owns 4,489,169 shares of the specialty pharmaceutical company’s stock valued at $49,516,000 after purchasing an additional 656,116 shares during the last quarter. Finally, CIBC World Markets Inc. boosted its holdings in shares of Valeant Pharmaceuticals International by 2.3% in the 2nd quarter. CIBC World Markets Inc. now owns 3,741,413 shares of the specialty pharmaceutical company’s stock valued at $64,726,000 after purchasing an additional 83,592 shares during the last quarter. Institutional investors own 50.47% of the company’s stock.

Several research firms recently weighed in on VRX. HC Wainwright restated a “hold” rating and set a $17.00 target price on shares of Valeant Pharmaceuticals International in a report on Monday, September 18th. Piper Jaffray Companies restated a “sell” rating and set a $14.00 target price on shares of Valeant Pharmaceuticals International in a report on Sunday, September 17th. Vetr upgraded shares of Valeant Pharmaceuticals International from a “strong sell” rating to a “sell” rating and set a $12.46 target price on the stock in a report on Monday, September 18th. ValuEngine lowered shares of Valeant Pharmaceuticals International from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Finally, Cantor Fitzgerald restated a “buy” rating and set a $23.00 target price on shares of Valeant Pharmaceuticals International in a report on Tuesday, August 29th. Five equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have issued a buy rating to the company’s stock. Valeant Pharmaceuticals International presently has a consensus rating of “Hold” and an average target price of $17.62.

WARNING: This piece was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/09/24/valeant-pharmaceuticals-international-inc-vrx-shares-sold-by-columbus-hill-capital-management-l-p.html.

In related news, Director Schutter Richard U. De purchased 10,000 shares of Valeant Pharmaceuticals International stock in a transaction on Monday, August 21st. The stock was purchased at an average cost of $14.33 per share, with a total value of $143,300.00. Following the acquisition, the director now directly owns 77,479 shares in the company, valued at $1,110,274.07. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 5.87% of the stock is owned by corporate insiders.

Valeant Pharmaceuticals International, Inc. (NYSE VRX) traded down 1.55% during midday trading on Friday, hitting $14.01. 4,770,255 shares of the stock traded hands. The company has a 50-day moving average of $14.22 and a 200-day moving average of $13.18. Valeant Pharmaceuticals International, Inc. has a 1-year low of $8.31 and a 1-year high of $27.84. The stock’s market cap is $4.88 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.97 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The firm had revenue of $2.23 billion during the quarter, compared to the consensus estimate of $2.23 billion. During the same period in the prior year, the firm earned ($0.88) EPS. The business’s revenue was down 7.7% on a year-over-year basis. On average, equities analysts expect that Valeant Pharmaceuticals International, Inc. will post $3.89 EPS for the current fiscal year.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.